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Ramadan fasting represents one of the five pillars of the Islam creed. Even though some 
subjects (among which patients) are exempted from observing this religious duty, they 
may be eager to share this particular moment of the year with their family and peers. 
However, there are no guidelines or standardized protocols that can help physicians 
to properly address the issue of patients with cancer fasting in Ramadan and correctly 
advising them. Moreover, in a more interconnected and globalized society, in which more 
and more Muslim patients live in the Western countries, this topic is of high interest also 
for the general practitioner. For this purpose, we carried out a systematic review on the 
subject. Our main findings are that (1) very few studies have been carried out, addressing 
this issue, (2) evidence concerning quality of life and compliance to treatment is contrast-
ing and scarce, and (3) generally speaking, few patients ask their physicians whether 
they can safely fast or not. For these reasons, further research should be performed, 
given the relevance and importance of this topic.
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inTRODUCTiOn
The Arabic word Islam means peace, purity, and total submission to the will of Allah (the Lord of the 
worlds, Rabb al-‘alameen) by conforming inwardly and outwardly to his law. The religion of Islam is 
based on five pillars (arkan al-Islam), and Ramadan fasting is one of these pillars.
In particular, Ramadan fasting represents a particular form of fasting, in that consists of alternate 
fasting and feasting (re-feeding) periods (1). Being based on the lunar calendar, mean fasting dura-
tion varies depending on the period of the year and the latitude of the place (1, 2).
A number of subjects, including patients, are usually exempted from this duty even though they 
could be willing to fast for taking part into the atmosphere of this particular moment (3).
It is a common saying that religion promotes healthy lifestyles. However, the relationship between 
a religion and cancer has been often overlooked or poorly addressed from a scientific, rigorous point 
of view (4), especially in terms of physiology (5). Among the few studies available in the literature, 
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Mills and collaborators investigated Seventh-Day Adventists. This 
religious group does not consume tobacco, alcohol, or pork and 
is characterized by lower cancer-related morbidity rates than the 
general population, even though the risk for prostate and endo-
metrial cancer was higher (6). Fraser noticed that non-vegetarian 
Seventh-Day Adventists were significantly more affected by colo-
rectal and prostate cancer than vegetarian Seven-Day Adventists 
(7–9), as well as of meningioma and glioma (10). Seventh-Day 
Adventists present also a particular relationship between cancer 
risk and allergy (11). Ogata and coworkers found a lower mortal-
ity from respiratory cancers among Zen Buddhists with respect to 
the general population (12). Sriplung and collaborators found that 
a lower incidence of cervical and breast cancers in Muslim than in 
Buddhist females. Furthermore, they noticed a lower incidence of 
prostate cancer in Muslim males. Independent of sex and year of 
diagnosis, the incidence of lung, liver, non-Hodgkin lymphoma 
(NHL), and colorectal cancers was lower in Muslims (13). Islamic 
beliefs can have an impact on access to breast or cervical cancer 
screening programs and therefore should be carefully taken into 
account by health workers in the field of Public Health (14–28).
The effects of Ramadan fasting on patients suffering from 
cancer interest physicians in that, in the nowadays globalized 
society, have to face with issues such as the management of cancer 
in Muslim patients (29).
In principle, clinical investigations carried out among patients 
suffering from cancer fasting during Ramadan could have broad, 
translational implications. The effects of fasting on cancer have 
been extensively studied: starvation-induced changes in genome 
organization, chromatin remodeling, and metabolic pathways 
modulating, for example, glucose, insulin-growth factor (IGF), 
and other related enzymes and proteins may increase the effec-
tiveness of chemotherapy (30–32). Fasting has an anti-Warburg 
effect and could have a positive impact on drug pharmacokinet-
ics and could contribute to reduce its side effects, improve the 
chemotherapeutic index, and overcome at least partially the issue 
of drug resistance (30–32). Furthermore, fasting has a beneficial 
impact on the renewal of stem cells and on the immune system, 
in particular on natural killer cells, as well as on the oxidant 
system, thus enabling cancer growth control (33–36). To this 
respect, different kinds of cancer have been investigated, such 
as pancreatic (37), breast (38–40), lung (41), colorectal (42) and 
prostate (43) cancer, and even glioma (44). The impact of fasting 
has been assessed on different drugs (45, 46), including irinotecan 
(47, 48), doxorubicin (49), and on new recent anti-blastics, such 
as erlotinib (41), tyrosine kinase inhibitors (50), and sirtuin (51), 
among others.
Effects of fasting on tumor have been assessed both on neo-
adjuvant and adjuvant therapy (40). Furthermore, fasting seems 
to sensitize tumor cells and increase the outcome of radiation 
therapy (44).
However, despite that this topic has attracted an impressive 
body of research (52, 53), little is known both in terms of molecu-
lar mechanisms and clinical outcomes about the difference 
among the various existing kinds of fasting, such as periodic diet 
(54), calories restriction (55), dietary restriction (56) or dietary 
manipulation (53), intermittent (38, 43, 57) or short-term fast-
ing (40, 49), and prolonged fasting (33, 35, 39), among others. 
Lv and collaborators in a recently published systematic review 
and meta-analysis concluded that while the roles of ketogenic 
diet and of caloric restriction in controlling cancer are quite 
established, evidence of the effectiveness of intermittent fasting 
is still insufficient (57). Furthermore, most of these studies have 
been conducted in animal models; therefore, there is an urgent 
need for more investigations in human (58).
Ramadan represents a unique laboratory for studying the 
effect of fasting in cancer patients, using a multidisciplinary 
approach. Aspects such as diabetic patients (59) or with renal 
(60, 61), infectious (62), or cardiovascular diseases (63) have been 
already reviewed.
However, there is a dearth of information concerning cancer 
patients willing to fast during Ramadan. For this purpose, we 
have carried out a systematic review, mining different databases, 
such as ISI/Web of Science (WoS), MEDLINE/PubMed, Scopus, 
Scirus, Directory of Open Access Journals (DOAJ), and Google 
Scholar.
RAMADAn AnD CAnCeR: QUALiTY OF 
LiFe AnD ADHeRenCe TO ReLiGiOUS 
wORSHiP
Kuzu and collaborators (29) investigated quality of life and com-
pliance to religious duties (such as praying and fasting) in 178 
patients living with a permanent colostomy. Seventy-five under-
went abdominoperineal resection (APR, or Miles’ operation), 51 
sphincter-saving resection, and 52 anterior resection, including 
sigmoid colectomy. Quality of life was measured with the Medical 
Outcomes Study Short Form 36 Health Survey (SF-36) and a 
questionnaire with items about work, sexual life, and compliance 
to religious worship. They found that a significantly number of 
patients in the APR group stopped praying daily (either alone or 
in a mosque) and fasting during Ramadan. They concluded that 
colorectal cancer, besides affecting quality of life, has a profound 
impact on religious worship. The authors recommended a preop-
erative counseling, involving local religious authorities.
Celasin and coworkers (64) carried out a prospective study 
recruiting 93 Muslim patients after surgery for colorectal carci-
noma: 50 underwent APR, 22 sphincter-saving resection, and 1 
anterior resection, including sigmoid colectomy. Quality of life was 
assessed pre- and postoperatively at 15–18 months with the SF-36 
questionnaire and a modified version of the American Society of 
Colorectal Surgeons (ASCRS) Fecal Incontinence questionnaire. 
Life standards, including religious practice, were measured using 
the Ankara University Life Standard Questionnaire (AULSQ). 
Authors found that religious worship (praying alone, praying 
in mosques, fasting during Ramadan, and purifying alms) was 
not significantly different among the groups. Probably, this was 
the effect of a proper religious counseling and its importance, 
advocated by Kuzu and collaborators in the previous article (29), 
is here confirmed.
Zeeneldin and Taha (65) conducted a cross-sectional 
study during Ramadan, August–September 2009, investigat-
ing 102 patients suffering from breast cancer (31%), acute 
leukemia (24%), colorectal cancer (7%), NHL (5%), bladder 
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cancer (4%), lung cancer (4%), and laryngeal cancer (4%). 
Treatments included chemotherapy, radiotherapy, hormonal 
therapy, and non-specific therapy in 42, 31, 10, and 17%, 
respectively. Comorbidities were present in 22% of the 
patients. Authors found that 40% of patients did not fast 
during Ramadan, 36 and 24% were partial and complete 
fasters. Being female patients, having a good and stable per-
formance status, suffering from a non-metastatic solid tumor, 
and receiving non-intravenous chemotherapy as outpatients 
were found to be predictor of compliance to fasting. However, 
only 46% of patients sought the treating oncologist advice on 
whether they could fast.
Altuntas and coworkers (66) carried out a prospective study 
investigating 56 patients with a cancer-related fecal stoma over 
two periods of Ramadan to analyze the effect of fasting on nutri-
tional and metabolic status and quality of life. Fourteen patients 
were fasting. They had their stoma for a longer period of time 
than patients in the non-fasting group, and the proportion of 
patients with a permanent stoma was higher in the fasting group 
than in the non-fasting group. Ramadan fasting had almost no 
influence on quality of life.
Tas and collaborators (67) performed a survey of 701 adult 
Turkish Muslim cancer patients during the month of Ramadan 
in 2012. Before diagnosis of cancer, 93.1% of the patients used 
to fast completely or partially. After diagnosis of cancer, this rate 
fell down to 15%: 83.9% of patients who fasted before diagnosis, 
gave up observing the religious duty. Patients who decided to go 
on fasting after the diagnosis of cancer thought that observing 
Ramadan would have lead to Patients who were females, those 
with good performance status, those without any comorbid dis-
ease (in particular, diabetes mellitus), who had non-metastatic 
disease, those with history of surgery, young, those treated with 
radiotherapy, and those being treated with single agents, oral 
chemotherapeutic agents, or not receiving drugs being in the 
follow-up period were more likely to be fasting than others. The 
fasting ones suffered from lymphoma, urogenital cancer (in par-
ticular, testicular tumor), and breast cancer; conversely, the rate 
of fasting status among patients with lung and gastrointestinal 
cancer was quite low. Gynecologic, head and neck, sarcoma, and 
skin cancers did not correlate with fasting status. Only 20.8% of 
all patients asked their physician whether it was alright for them 
to fast and physicians generally had a negative attitude toward 
fasting (83.2%). About 13.3% of physicians allowed patients to 
choose whether to fast or not. Physicians were concerned about 
the possibility of fasting in patients at risk of tumor lysis syn-
drome, taking nephrotoxic drugs, or other drugs that could lead 
to vomiting, diarrhea, or renal failure. The authors concluded that 
majority of cancer patients are not fasting during the month of 
Ramadan, and a small part of patients consult this situation to 
their physician.
RAMADAn AnD CAnCeR: ADHeRenCe 
TO DRUG TReATMenT
Drug compliance during Ramadan generally tends to fall, as 
noticed by some scholars (68–70).
Other authors, such as Zeeneldin and coauthors (71), how-
ever, have found that Ramadan fasting does not impair patient’s 
adherence to treatment. During Ramadan 2010, 139 patients 
suffering from breast cancer were asked about compliance to 
fasting and religious duties as well as to treatment with oral 
hormonal therapy (OHT) in Ramadan and in the preceding 
month. Tamoxifen and aromatase inhibitors were used in 64 and 
36%, respectively. Adherence rates to OHT during Ramadan and 
before were 94.2 and 95.7%, respectively (not statistically signifi-
cant). Non-adherence prior to Ramadan and shorter duration of 
OHT were predictors of non-adherence during Ramadan, while 
fasting status, age, performance status, presence of metastases, 
and type of OHT were not good predictors of adherence.
ReSULTS AnD DiSCUSSiOn
Despite our extensive search, we managed to find only six studies 
addressing the issue of patients suffering from cancer fasting dur-
ing Ramadan: in particular, five focusing on the impact of fasting 
on quality of life and compliance to worship and one focusing 
on adherence to drug treatment. Despite the importance and 
relevance of this topic and given the burden imposed by the can-
cer, very few scholars have investigated the impact of Ramadan 
fasting on the health of patients with tumor.
The effect of Ramadan on quality of life appears to be contro-
versial: while three studies confirm this relationship, two other 
researches fail to find any impact. Also, the effect of fasting on 
compliance to worship seems to be quite contrasting.
As far as the compliance to drug treatment is concerned, there 
is only one study available, and therefore it is not possible to col-
lect any evidence.
COnCLUSiOn
There is a strong need for evidence-based suggestions and guide-
lines (3). Very few studies are available, with contrasting findings.
The management of Muslim patients suffering from cancer is 
very complex and should involve a multidisciplinary team, made up 
of an oncologist, a nutritionist, a psychiatrist, or a psychologist, who 
should be aware of the importance of cultural and spiritual beliefs 
in medicine (5), and in particular in the oncology practice (72).
A diagnosis of cancer is always difficult to cope with and in 
Muslim subjects can have a varying impact, depending also on the 
degree of religiosity of the subjects itself. Errihani and colleagues 
found that in practicing Muslims cancer is seen as a divine test 
and as such accepted, while non-practicing Muslims feel guilty 
and begin to practice (73). Therefore, the level of spirituality/
religiosity plays a major role in supporting the patient during 
the health-care process and can influence the clinical outcome. 
However, as found by the study of Tas and collaborators (67), 
the communication between the patient and the physician is not 
always characterized by an open disclosure and a frank dialog. 
This is further complicated by the fact that the situation is rather 
delicate and the doctor, if not culturally competent or sensitive, 
could be left with dilemmas because of the cultural/religious 
beliefs and attitudes of the patient (74).
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Oncologists should carefully assess the health conditions of 
patients and discourage them to fast if they present metastasis or 
particularly disseminated, aggressive forms of cancer or if they 
have a history of non-compliance/non-adherence to pharmaco-
logical and/or dietary treatment.
On the contrary, patients with a strong motivation to fast 
should be encourage, in that spirituality/religiosity plays a 
major role in cancer. The patient feels indeed himself/herself 
more active being involved in the religious activities, and less 
depressed and isolated (3). Furthermore, there is a solid scien-
tific evidence that fasting, activating certain neuroendocrine 
pathways and leading to the release of neurotrophic factors, can 
enhance the mood and relieve the pain in patients suffering from 
chronic disorders (75).
A particular aspect that should be addressed is the manage-
ment of terminal patients during Ramadan, especially in terms of 
terminal nutrition (76). From the literature, it is known that some 
Muslim patients with terminal illnesses may express a strong 
spiritual and religious wish (77, 78). This calls for cooperation 
between the family and the interdisciplinary palliative care team. 
On the contrary, some scholars, like Tas and collaborators (67), 
have shown that there is poor cooperation between physician and 
patient. Facing patients’ needs is likely to have a great positive 
impact on the patient’s sense of wellbeing.
However, once again, also this topic has been poorly explored, 
despite the clinical importance of fasting (79). Therefore, further 
research in the field is needed.
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